摘要
Background and Objective: Anatomic lobectomy has long been considered the standard operation for early-stage non-small cell lung cancer (NSCLC), largely based on the Lung Cancer Study Group 821 (LCSG 821) trial, which penalized “limited resection” in an era of rudimentary imaging, heterogeneous techniques, and inconsistent nodal assessment. With advances in imaging, staging, and parenchyma-sparing surgery, the role of sublobar resection has been fundamentally re-examined. This review aims to synthesize contemporary evidence comparing oncologic and functional outcomes of lobectomy, segmentectomy, and wedge resection to inform optimal surgical decision-making in early-stage NSCLC. Methods: This narrative review synthesizes evidence from randomized controlled trials, large observational studies, and contemporary guideline statements comparing lobectomy, segmentectomy, and wedge resection for early-stage NSCLC. A comprehensive literature search was conducted using PubMed, EMBASE, the Cochrane Library, and Google Scholar. Included studies were limited to English-language publications. Key Content and Findings: Modern randomized trials such as JCOG0802/WJOG4607L and CALGB/Alliance 140503 now demonstrate that anatomic segmentectomy is oncologically noninferior to lobectomy for carefully selected peripheral stage IA tumors ≤2 cm, and emerging data suggest similar survival for selected 2–3 cm (T1c) tumors when margins and nodal evaluation are adequate. In contrast, wedge resection shows a modest population-level penalty in locoregional control and lung cancer-specific survival. Notably, when a margin-to-tumor ratio ≥1 is achieved with systematic nodal staging, high-quality wedge resections can approximate segmentectomy outcomes in subsolid nodules and carefully selected frail patients. Ongoing trials are testing sublobar resection in “gray zone” settings, including larger pure-solid tumors, patients with idiopathic pulmonary fibrosis, and patients with multiple primaries, and comparative studies continue to refine its role relative to stereotactic body radiation therapy. Conclusions: This review outlines contemporary randomized data, large registry analyses, and consensus guidelines to clarify when segmentectomy and wedge resection can be used without compromising oncologic outcomes. It aims to move current surgical practice beyond a rigid “lobectomy-or-nothing” paradigm toward individualized, parenchyma-sparing surgery, in which the choice among lobectomy, segmentectomy, and wedge resection is guided by tumor biology, anatomy, and patient-specific risk rather than a fixed hierarchy of procedures.